


**ESM accompanying the original article “Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial” by Tonneijck L et al**

**ESM Fig. 3** Blood glucose response to intravenous GLP-1RA exenatide administration in overweight patients with type 2 diabetes



Blood glucose decreased after exenatide infusion by a time-averaged mean of  $1.4 \pm 0.1$  mmol/l compared with placebo ( $p < 0.001$ ).